PTPRT and cancer: In addition, several immune inhibitory molecules, including LAG3, CD96, CTLA4, PDCD1, BTLA, IDO1, CD274, and TIGIT, were enriched in PTPRD/PTPRT mutant cancers, all of which are crucial immune checkpoints for anti-tumor drugs (all P < 0.05) (Figure 8D).